The Canadian cannabis industry has developed into a leader in cannabis used for medicinal purposes, and the Canadian capital markets have supported its development by providing readily available sources of capital to industry players.
With the imminent legalisation of cannabis for recreational purposes, the use of cannabis in everyday life raises legal questions about its regulation and potential health and other risks. It has also created additional opportunities for capital raising in Canada by Canadian and international participants, as well as significant opportunities for M&A activity across the industry.
This webinar will canvass the following topics:
John Sabetti is a partner of the Canadian law firm Fasken Martineau and a member of the securities and M&A group’s steering committee. He practises primarily in the areas of securities, M&A and corporate commercial law. As the Canadian cannabis industry has evolved, he has been involved in structuring and implementing the go-public and capital-raising transactions, and stock exchange listings, of numerous issuers, both Canadian and foreign. He has also been involved in raising capital for ancillary businesses that provide products to the cannabis industry, including issuers that provide cannabis stream financing. In addition, as the Canadian cannabis sector has experienced recent consolidation, he has been involved in various aspects of certain M&A transactions. His clients in the cannabis sector range from industry players to many of the prominent Canadian investment banks that have taken lead roles in the sector. He is recognised by various legal industry publications as a leading lawyer for capital markets and M&A.
Christelle Gedeon is the chief legal officer of Aphria Inc, a Canadian licensed producer of cannabis that is listed on the Toronto Stock Exchange. Before joining Aphria, she was a partner of Fasken Martineau DuMoulin LLP, with a practice that focused on the life sciences industry, specifically on products regulated under the Food and Drugs Act, including drugs, devices, food, cosmetics and cannabis. She is a regulatory affairs specialist and has substantial experience in preparing regulatory submissions for medical devices, pharmaceutical products, cosmetics, foods and cannabis products. In particular, she has expertise in relation to Health Canada’s regulatory regime respecting cannabis and has substantial experience in applying for licences under the Access to Cannabis for Medical Purposes Regulations and the Narcotic Control Regulations. Most recently, she has focused on the new rules under the Cannabis Act and the Cannabis Regulations that are scheduled to come into force in October 2018.